Developing next-generation solutions for restenosis and other cardiovascular clinical applications.
Integrated drug eluting stent (DES) company developing next-generation solutions for restenosis and other cardiovascular clinical applications. X-Cell’s lead program uses 17-ß-estradiol on DES which enhances endothelial growth to help combat sub-acute thrombosis.
Share buy back in 2007.
Human Health
Industry
Biotech
Status
Realised
Location
US